
What is claimed is:

1. A compound of formula I



I

or a salt thereof, wherein:

R^1 is H, -Cl, -F, -Br, -I, -OH, -CN, -NO_2, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 alkenyl, substituted or unsubstituted cycloalkyl, aryl or heteroaryl;


R^3 is $-[(CH_2)_2E]_n(CH_2)_2NR'R''$ and n is any integer from 0 through 30,

wherein R' and R" are each independently H, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 alkenyl, or substituted or unsubstituted cycloalkyl;

aryl is any substituted or unsubstituted fully or partially aromatic hydrocarbon substituent or heteroaryl substituent;


Y^1 and Y^3 are independently C, O, N, NR^2 or S, wherein R^2 is H, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 alkenyl, substituted or unsubstituted cycloalkyl, aryl or heteroaryl;

Y^2 is C or N;


A and D are independently  amidine, thioamide or A and/or D is absent;

B is substituted or unsubstituted C_4-C_9-cycloalkyl, substituted or unsubstituted C_4-C_9-heterocycloalkyl comprising N, O or S, substituted or unsubstituted heteroaryl comprising N, O , S or B is absent;

C is any of

A and D are independently , amidine, thioamide or A and/or D is absent;

B is substituted or unsubstituted C_4-C_9-cycloalkyl, substituted or unsubstituted C_4-C_9-heterocycloalkyl comprising N, O or S, substituted or unsubstituted heteroaryl comprising N, O , S or B is absent;

C is any of , aryl, heteroaryl, amidine, or thioamide;

E is CH_2, O, NH or S, or E is absent; and

Z is substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl comprising N, O or S, or substituted or unsubstituted heteroaryl comprising N, O, S or Z is absent.

21. A compound according to any one of claims 1 to 19, wherein each of D, Z (or Z_0), A, and B is absent.

22. A compound according to any one of claims 1 to 21 for use in therapy.


23. A pharmaceutical composition comprising a therapeutic agent and a compound according to any one of claims 1 to 21.

24. A method of treating a patient with a pharmaceutical composition according to claim 23.

25. A method of extending the half life of a therapeutic agent comprising conjugating the agent to a compound according to any one of claims 1 to 21 and administering it to a patient.


26. An affinity chromatography solid phase comprising a compound according to any one of claims 1 to 21.

27. A method of purifying a protein of interest using a compound according to any one of claims 1 to 21.

A and D are independently , amidine, thioamide or A and/or D is absent;

B is substituted or unsubstituted C_4-C_9-cycloalkyl, substituted or unsubstituted C_4-C_9-heterocycloalkyl comprising N, O or S, substituted or unsubstituted heteroaryl comprising N, O , S or B is absent;

C is any of

, aryl, heteroaryl, amidine, or thioamide;

E is CH_2, O, NH or S, or E is absent; and

Z is substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl comprising N, O or S, or substituted or unsubstituted heteroaryl comprising N, O, S or Z is absent.

21. A compound according to any one of claims 1 to 19, wherein each of D, Z (or Z_0), A, and B is absent.

22. A compound according to any one of claims 1 to 21 for use in therapy.

23. A pharmaceutical composition comprising a therapeutic agent and a compound according to any one of claims 1 to 21.

24. An affinity chromatography solid phase comprising a compound according to any one of claims 1 to 21.

25. A method of purifying a protein of interest using a compound according to any one of claims 1 to 21.